197 related articles for article (PubMed ID: 36961891)
1. Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology.
Hess NJ; Turicek DP; Riendeau J; McIlwain SJ; Contreras Guzman E; Nadiminti K; Hudson A; Callander NS; Skala MC; Gumperz JE; Hematti P; Capitini CM
Sci Adv; 2023 Mar; 9(12):eadf0567. PubMed ID: 36961891
[TBL] [Abstract][Full Text] [Related]
2. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
3. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
[TBL] [Abstract][Full Text] [Related]
5. A Novel Xenogeneic Graft-Versus-Host Disease Model for Investigating the Pathological Role of Human CD4
Ito R; Katano I; Kawai K; Yagoto M; Takahashi T; Ka Y; Ogura T; Takahashi R; Ito M
Am J Transplant; 2017 May; 17(5):1216-1228. PubMed ID: 27862942
[TBL] [Abstract][Full Text] [Related]
6. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
Hossain MS; Kunter GM; El-Najjar VF; Jaye DL; Al-Kadhimi Z; Taofeek OK; Li JM; Waller EK
PLoS One; 2017; 12(9):e0184254. PubMed ID: 28953925
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 serves as a double agent in separating GVL from GVHD.
Brennan TV; Yang Y
J Clin Invest; 2017 May; 127(5):1627-1630. PubMed ID: 28414300
[TBL] [Abstract][Full Text] [Related]
8. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function.
Wu Y; Tang CA; Mealer C; Bastian D; Hanief Sofi M; Tian L; Schutt S; Choi HJ; Ticer T; Zhang M; Sui X; Huang L; Mellor AL; Hu CA; Yu XZ
Cell Mol Immunol; 2021 Mar; 18(3):632-643. PubMed ID: 33500563
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
10. Mocravimod, a S1P receptor modulator, increases T cell counts in bone marrow biopsies from patients undergoing allogeneic hematopoietic stem cell transplantation.
Dertschnig S; Passweg J; Bucher C; Medinger M; Tzankov A
Cell Immunol; 2023 Jul; 388-389():104719. PubMed ID: 37141843
[TBL] [Abstract][Full Text] [Related]
11. Nrf2 regulates CD4
Tsai JJ; Velardi E; Shono Y; Argyropoulos KV; Holland AM; Smith OM; Yim NL; Rao UK; Kreines FM; Lieberman SR; Young LF; Lazrak A; Youssef S; Fu YY; Liu C; Lezcano C; Murphy GF; Na IK; Jenq RR; Hanash AM; Dudakov JA; van den Brink MRM
Blood; 2018 Dec; 132(26):2763-2774. PubMed ID: 30381375
[TBL] [Abstract][Full Text] [Related]
12. CD8+CD44(hi) but not CD4+CD44(hi) memory T cells mediate potent graft antilymphoma activity without GVHD.
Dutt S; Baker J; Kohrt HE; Kambham N; Sanyal M; Negrin RS; Strober S
Blood; 2011 Mar; 117(11):3230-9. PubMed ID: 21239702
[TBL] [Abstract][Full Text] [Related]
13. During acute graft versus host disease CD28 deletion in donor CD8
Uri A; Lühder F; Kerkau T; Beyersdorf N
Eur J Immunol; 2018 Dec; 48(12):2055-2067. PubMed ID: 30320878
[TBL] [Abstract][Full Text] [Related]
14. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
15. S1P/S1PR1 signaling differentially regulates the allogeneic response of CD4 and CD8 T cells by modulating mitochondrial fission.
Tian L; Wu Y; Choi HJ; Sui X; Li X; Sofi MH; Kassir MF; Chen X; Mehrotra S; Ogretmen B; Yu XZ
Cell Mol Immunol; 2022 Nov; 19(11):1235-1250. PubMed ID: 36071219
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
17. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans.
Stanzani M; Martins SL; Saliba RM; St John LS; Bryan S; Couriel D; McMannis J; Champlin RE; Molldrem JJ; Komanduri KV
Blood; 2004 Feb; 103(3):1140-6. PubMed ID: 12907445
[TBL] [Abstract][Full Text] [Related]
18. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
Sykes M; Abraham VS; Harty MW; Pearson DA
J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
[TBL] [Abstract][Full Text] [Related]
19. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.
Shrestha B; Walton K; Reff J; Sagatys EM; Tu N; Boucher J; Li G; Ghafoor T; Felices M; Miller JS; Pidala J; Blazar BR; Anasetti C; Betts BC; Davila ML
J Clin Invest; 2020 Sep; 130(9):4652-4662. PubMed ID: 32437331
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
